Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard N Channick

Showing results (91-100 of 106) with videos related to

Pageof 11
Sort By:
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|February 17, 2020
Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON studyOlivier Sitbon, Kelly M Chin, Richard N Channick, et al.
Pulmonary Circulation|November 18, 2021
TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertensionRobert P Frantz, Raymond L Benza, Richard N Channick, et al.
Circulation. Cardiovascular Imaging|January 12, 2019
Quantification of the Pulmonary Vascular Response to Inhaled Nitric Oxide Using Noncontrast Computed Tomography ImagingFarbod Nicholas Rahaghi, Tilo Winkler, Puja Kohli, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|November 4, 2017
Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI<sub>2</sub>) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) studyIoana R Preston, Richard N Channick, Kelly Chin, et al.
The New England Journal of Medicine|August 30, 2013
Macitentan and morbidity and mortality in pulmonary arterial hypertensionTomás Pulido, Igor Adzerikho, Richard N Channick, et al.
Chest|June 6, 2021
Results From the United States Chronic Thromboembolic Pulmonary Hypertension Registry: Enrollment Characteristics and 1-Year Follow-upKim M Kerr, C Greg Elliott, Kelly Chin, et al.
JACC. Cardiovascular Interventions|April 29, 2026
Balloon Pulmonary Angioplasty for Treatment of Chronic Thromboembolic Pulmonary Hypertension: Statement From the BPA-CTEPH AllianceWilliam R Auger, Richard A Krasuski, Ehtisham Mahmud, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|January 19, 2020
Circulating NEDD9 is increased in pulmonary arterial hypertension: A multicenter, retrospective analysisAndriy O Samokhin, Steven Hsu, Paul B Yu, et al.
Pulmonary Circulation|May 17, 2021
Significance of autoimmune disease in severe pulmonary hypertension complicating extensive pulmonary fibrosis: a prospective cohort studyRajeev Saggar, Paresh C Giri, Chunqin Deng, et al.
Journal of the American College of Cardiology|February 16, 2018
Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for MortalityVallerie V McLaughlin, Marius M Hoeper, Richard N Channick, et al.
Pageof 11

Showing results (91-100 of 106) with videos related to

Sort By:
Pageof 11
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|February 17, 2020
Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON studyOlivier Sitbon, Kelly M Chin, Richard N Channick, et al.
Pulmonary Circulation|November 18, 2021
TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertensionRobert P Frantz, Raymond L Benza, Richard N Channick, et al.
Circulation. Cardiovascular Imaging|January 12, 2019
Quantification of the Pulmonary Vascular Response to Inhaled Nitric Oxide Using Noncontrast Computed Tomography ImagingFarbod Nicholas Rahaghi, Tilo Winkler, Puja Kohli, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|November 4, 2017
Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI<sub>2</sub>) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) studyIoana R Preston, Richard N Channick, Kelly Chin, et al.
The New England Journal of Medicine|August 30, 2013
Macitentan and morbidity and mortality in pulmonary arterial hypertensionTomás Pulido, Igor Adzerikho, Richard N Channick, et al.
Chest|June 6, 2021
Results From the United States Chronic Thromboembolic Pulmonary Hypertension Registry: Enrollment Characteristics and 1-Year Follow-upKim M Kerr, C Greg Elliott, Kelly Chin, et al.
JACC. Cardiovascular Interventions|April 29, 2026
Balloon Pulmonary Angioplasty for Treatment of Chronic Thromboembolic Pulmonary Hypertension: Statement From the BPA-CTEPH AllianceWilliam R Auger, Richard A Krasuski, Ehtisham Mahmud, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|January 19, 2020
Circulating NEDD9 is increased in pulmonary arterial hypertension: A multicenter, retrospective analysisAndriy O Samokhin, Steven Hsu, Paul B Yu, et al.
Pulmonary Circulation|May 17, 2021
Significance of autoimmune disease in severe pulmonary hypertension complicating extensive pulmonary fibrosis: a prospective cohort studyRajeev Saggar, Paresh C Giri, Chunqin Deng, et al.
Journal of the American College of Cardiology|February 16, 2018
Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for MortalityVallerie V McLaughlin, Marius M Hoeper, Richard N Channick, et al.
Pageof 11